key: cord-0760124-h6z9bs2w
authors: Arduino, Paolo G.; Gambino, Alessio; Broccoletti, Roberto
title: SARS‐CoV‐2 infection does not seem to worsen the clinical course of patients with oral autoimmune disease
date: 2021-08-09
journal: Oral Dis
DOI: 10.1111/odi.13990
sha: f39bc407bf715272565b05f22b4db3137216d32c
doc_id: 760124
cord_uid: h6z9bs2w

nan

Since December 2020 to May 2021, we prospectively collected data in a cohort of Caucasian patients visited in our oral medicine section, with a previously confirmed histopathological and clinical diagnosis of OLP, MMP, or PV. The diagnosis of COVID-19 was based on typical clinical findings and positive real-time polymerase chain reaction (PCR) for SARS-CoV-2 or lung involvement compatible with COVID-19 on chest computed tomography (CT) scan, as suggested by World Health Organization guidelines (World Health Organization, 2020). All patients had a confirmed, mild-to-moderate COVID-19. Data about gender, age, smoking status, oral symptoms reported before and after COVID-19, worsening or stability of the oral condition compared to the last evaluation before COVID-19, type of medications used for the primary oral conditions, and type of recovery during COVID-19 (home care of need to be hospitalized) were detailed. Worsening has to be described as an increase in the severity of a disease or signs of the primary oral disease.

During the observational period, 647 patients were visited (Table 1) . Female patients seemed to be more susceptible to COVID-19 (p = .000), as well as smokers or those with a previous diagnosis of PV, irrespectively to the pharmacological status, but without statistical differences. We were not able to detect any differences in oral manifestation, compared to the last visit before February 2020, between the 2 groups.

According to recent publication, patients diagnosed with systemic autoimmune diseases do not seem to carry an increased risk of COVID-19 as compared to the general population (Emmi et al., 2020) . Moreover, even if it has been speculated that SARS-COV-2 infection could activate lymphocytes and inflammatory response, preliminary studies suggested that the risk of developing severe forms of COVID-19 in patients with AD, treated with immunomodulators or biologics, might not increase (Li et al., 2021 

Sjögren Big Data Consortium, Members of the EULAR-SS Task Force Big Data Consortium who contributed to this study

SARS-CoV-2 infection among patients with systemic autoimmune diseases

COVID-19 illness and autoimmune diseases: Recent insights

Oral mucosal manifestations of autoimmune skin diseases

Use of chest imaging in COVID-19: A rapid advice guide

SARS-CoV-2 infection does not seem to worsen the clinical course of patients with oral autoimmune disease